Abstract:One‐hundred‐eleven mismatched living related renal transplants have been analyzed to compare the benefits and drawbacks of two seemingly complimentary immunotherapy protocols. Sixty‐one recipients received cyclosporine (CsA) and prednisone and 50 received donor‐specific transfusions (DST) combined with azathioprine, prednisone, and prophylactic antilymphoblast globulin (ALG). At 2 years, both immunosuppressive protocols have a comparable low incidence of patient and allograft loss and a comparable low incidence of rejection and infectious episodes. However, the relative cost of transplantation at 6 months was decreased by 30% (p < 0.05) in recipients who received CsA following transplantation. Furthermore, CsA allows the potential recipient immediate access to mismatched living related donor (LRD) transplantation without running the risk of possible presensitization to their donor. Recipient presensitization with DST is a problem; however, DST with conventional therapy and ALG provides for an effective alternative method of immunosuppression. Long‐term analysis of renal allograft function must be evaluated in the CsA‐treated group to ascertain if pharmacologically induced nephrotoxicity will become a significant variable in the future.

Mismatched living related donor transplantation: Donor‐specific transfusions vs. cyclosporine